Detail akcie Ypsomed Holding online

Business Summary: Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Financial Summary: BRIEF: For the six months ended 30 September 2023, Ypsomed Holding AG revenues increased 5% to SF255.4M. Net income increased from SF15.4M to SF36.6M. Revenues reflect Delivery Systems segment increase of 23% to SF176.5M. Net income benefited from Foreign Exchange Loss decrease of 52% to SF2M (expense), Other Operating Income increase of 5% to SF3.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from SF1.17 to SF2.68.